Our attorneys have filed a mass tort lawsuit on behalf of individuals who took the blood thinner Xarelto (rivaroxaban) and suffered critical bleeding events. Pharmaceutical companies, like the makers of Xarelto, possess a duty to make sure that their drugs are reasonably secure for use – and failure to perform so may possibly be grounds for compensation. Our lawyers are operating difficult to get those hurt by the drug the compensation they may be entitled to.
Even though bleeding is actually a widespread complication connected with anticoagulants, it has been alleged that Xarelto is much more harmful than classic blood thinners simply because no antidote exists to reverse its blood-thinning effects. This signifies that, inside the event of an emergency, patients might be at threat for irreversible bleeding problems, including life-threatening internal and gastrointestinal hemorrhaging.
In case you or a loved one suffered a critical bleeding occasion right after taking Xarelto, you may have legal recourse. For much more info, contact us today to possess your case reviewed, totally free of charge.
xarelto-compensation-photoThe plaintiffs in these lawsuits are searching for compensation from Bayer and Janssen for past and future healthcare bills, lost wages, discomfort and suffering and, in circumstances of death, funeral expenditures. In addition, they’re seeking punitive damages, which are normally awarded to punish the defendant and deter other organizations from acting similarly.
Why Are Lawsuits Being Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is unsafe and defective. The plaintiffs claim that, unlike traditional anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Because of this, the lawsuits claim, doctors have no effective implies of stopping Xarelto users from bleeding inside the event of an emergency. Plaintiffs within the lawsuits allege critical and fatal injuries, including cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior in the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a protected anticoagulant option.
Doctors and health-related staff were not properly made aware of methods to stabilize and treat a Xarelto user within the occasion of a bleeding complication.
Users of Xarelto pharmaceutical company were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to serious bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing dangerous clotting.
Visit this page for far more data on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys inside the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.